444 related articles for article (PubMed ID: 30248193)
1. Drug Formulations: Standards and Novel Strategies for Drug Administration in Pediatrics.
Thabet Y; Klingmann V; Breitkreutz J
J Clin Pharmacol; 2018 Oct; 58 Suppl 10():S26-S35. PubMed ID: 30248193
[TBL] [Abstract][Full Text] [Related]
2. 10 years EU regulation of pediatric medicines - impact on cardiovascular drug formulations.
Thabet Y; Slavkova M; Breitkreutz J
Expert Opin Drug Deliv; 2018 Mar; 15(3):261-270. PubMed ID: 29284286
[TBL] [Abstract][Full Text] [Related]
3. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
Giacoia GP; Taylor-Zapata P; Zajicek A
Clin Ther; 2012 Nov; 34(11):S1-10. PubMed ID: 23149008
[TBL] [Abstract][Full Text] [Related]
4. Drug delivery and formulations.
Breitkreutz J; Boos J
Handb Exp Pharmacol; 2011; 205():91-107. PubMed ID: 21882107
[TBL] [Abstract][Full Text] [Related]
5. Patent landscape of pediatric-friendly oral dosage forms and administration devices.
Karavasili C; Gkaragkounis A; Fatouros DG
Expert Opin Ther Pat; 2021 Jul; 31(7):663-686. PubMed ID: 33605825
[TBL] [Abstract][Full Text] [Related]
6. Orodispersible tablets for pediatric drug delivery: current challenges and recent advances.
Wiedey R; Kokott M; Breitkreutz J
Expert Opin Drug Deliv; 2021 Dec; 18(12):1873-1890. PubMed ID: 34822316
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of two novel co-processed excipients for direct compression of orodispersible tablets and mini-tablets.
Kokott M; Lura A; Breitkreutz J; Wiedey R
Eur J Pharm Biopharm; 2021 Nov; 168():122-130. PubMed ID: 34474110
[TBL] [Abstract][Full Text] [Related]
8. Neonatal and pediatric oral drug delivery: Hopes and hurdles.
Mfoafo KA; Omidian M; Bertol CD; Omidi Y; Omidian H
Int J Pharm; 2021 Mar; 597():120296. PubMed ID: 33524524
[TBL] [Abstract][Full Text] [Related]
9. Pediatric drug formulations: a review of challenges and progress.
Ivanovska V; Rademaker CM; van Dijk L; Mantel-Teeuwisse AK
Pediatrics; 2014 Aug; 134(2):361-72. PubMed ID: 25022739
[TBL] [Abstract][Full Text] [Related]
10. Taste-masking methods in multiparticulate dosage forms with a focus on poorly soluble drugs.
Simšič T; Planinšek O; Baumgartner A
Acta Pharm; 2024 Jun; 74(2):177-199. PubMed ID: 38815202
[TBL] [Abstract][Full Text] [Related]
11. Issues impacting therapeutic outcomes in pediatric patients: an overview.
Kalra A; Goindi S
Curr Pediatr Rev; 2014; 10(3):184-93. PubMed ID: 25088338
[TBL] [Abstract][Full Text] [Related]
12. Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects.
van Riet-Nales DA; Schobben AF; Vromans H; Egberts TC; Rademaker CM
Arch Dis Child; 2016 Jul; 101(7):662-9. PubMed ID: 26979250
[TBL] [Abstract][Full Text] [Related]
13. Age-appropriate solid oral formulations for pediatric applications with a focus on multiparticulates and minitablets: Summary of September 2019 EuPFI workshop.
Harris D; Hermans E; Klein S; Wagner-Hattler L; Walsh J
Eur J Pharm Biopharm; 2020 Aug; 153():222-225. PubMed ID: 32580052
[TBL] [Abstract][Full Text] [Related]
14. Pediatric formulation development - Challenges of today and strategies for tomorrow: Summary report from M-CERSI workshop 2019.
Tan DCT; Khong YM; Mount S; Galella E; Mitra B; Charlton S; Kuhli M; Ternik R; Walsh J; Rajapakshe A; Thompson K; Mehrotra S; Santangelo M; Liu J; Dixit T; Schaufelberger D; Jamzad S; Klein S; Hoag SW; Wang J; Fletcher EP; Khurana M; Alexander J; Radden E; Sood R; Selen A
Eur J Pharm Biopharm; 2021 Jul; 164():54-65. PubMed ID: 33878432
[TBL] [Abstract][Full Text] [Related]
15. Acceptability of small-sized oblong tablets in comparison to syrup and mini-tablets in infants and toddlers: A randomized controlled trial.
Münch J; Meissner T; Mayatepek E; Wargenau M; Breitkreutz J; Bosse HM; Klingmann V
Eur J Pharm Biopharm; 2021 Sep; 166():126-134. PubMed ID: 34153451
[TBL] [Abstract][Full Text] [Related]
16. Playing hide and seek with poorly tasting paediatric medicines: do not forget the excipients.
Walsh J; Cram A; Woertz K; Breitkreutz J; Winzenburg G; Turner R; Tuleu C;
Adv Drug Deliv Rev; 2014 Jun; 73():14-33. PubMed ID: 24614069
[TBL] [Abstract][Full Text] [Related]
17. Development of nanoparticle-based orodispersible palatable pediatric formulations.
Deng Y; Shen L; Yang Y; Shen J
Int J Pharm; 2021 Mar; 596():120206. PubMed ID: 33493595
[TBL] [Abstract][Full Text] [Related]
18. Safe, swallowable and palatable paediatric mini-tablet formulations for a WHO model list of essential medicines for children compound - A promising starting point for future PUMA applications.
Freerks L; Sommerfeldt J; Löper PC; Klein S
Eur J Pharm Biopharm; 2020 Nov; 156():11-19. PubMed ID: 32871197
[TBL] [Abstract][Full Text] [Related]
19. Paediatric Drug Development and Formulation Design-a European Perspective.
Van Riet-Nales DA; Kozarewicz P; Aylward B; de Vries R; Egberts TC; Rademaker CM; Schobben AF
AAPS PharmSciTech; 2017 Feb; 18(2):241-249. PubMed ID: 27270905
[TBL] [Abstract][Full Text] [Related]
20. Age-appropriate and acceptable paediatric dosage forms: Insights into end-user perceptions, preferences and practices from the Children's Acceptability of Oral Formulations (CALF) Study.
Ranmal SR; Cram A; Tuleu C
Int J Pharm; 2016 Nov; 514(1):296-307. PubMed ID: 27863675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
